CAR-NK-Zellen: die nächste Innovation der Krebsimmuntherapie?

CAR-NK cells offer a promising immunotherapy approach, addressing key CAR-T cell limitations like reduced toxicity risks while retaining targeted efficacy. They combine the innate cytotoxicity of natural killer (NK) cells with the targeted action of chimeric antigen receptors (CAR). Their potential lies in efficacy, tolerability and the possibility of off-the-shelf production, enabling rapid treatment access. However, CAR-NK cells are still in early development with ongoing clinical trials. The next years will determine their potential for clinical application.